2504 Background: MT110 is a bispecific T cell engaging antibody construct (BiTE) that
directs CD3 expressing T cells to kill target cells that express EpCAM, which is widely found …

2573^ Background: MT110 is a bispecific antibody construct (BiTE) binding to epithelial cell
adhesion molecule (EpCAM) expressed on most solid cancers, and to CD3 on T cells …

Metastases to the central nervous system (CNS), a favored site for metastatic spread among
the more common cancers in the western developed countries, occur in 25–35% of all …

Background In several phase II and III topotecan studies the large number of patients with
stable disease is striking. Since no severe organ toxicity has been described for topotecan …

Objective: Topotecan and gemcitabine have shown mono-activity against different solid
tumors including recurrent ovarian cancer after failure of platinum-and paclitaxel-containing …

Aim: Topotecan and gemcitabine have demonstrated mono‐activity against recurrent
ovarian cancer. Both drugs affect DNA replication; in addition, topotecan inhibits DNA repair …

Purpose Topotecan is generally well tolerated and active in patients with relapsed small-cell
lung cancer (SCLC) and poor performance status (PS). In this study, we investigated …

Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-
term therapy with topotecan vs. standard treatment duration in patients with recurrent …

The pattern of molecular forms of acetylcholinesterase (AChE) was studied by
polyacrylamide gel electrophoresis in the cerebral ganglion of P. americana during …

Objective: The purpose of this study was to determine the incidence of lymph node and
ovarian metastases in newly diagnosed uterine leiomyosarcoma (LMS). Methods: We used …